Does applying technology throughout the medication use process improve patient safety with antineoplastics?

Joseph Bubalo, Bruce A. Warden, Joshua J. Wiegel, Tess Nishida, Evelyn Handel, Leanne M. Svoboda, Lam Nguyen, P. Neil Edillo

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Purpose: Medical errors, in particular medication errors, continue to be a troublesome factor in the delivery of safe and effective patient care. Antineoplastic agents represent a group of medications highly susceptible to medication errors due to their complex regimens and narrow therapeutic indices. As the majority of these medication errors are frequently associated with breakdowns in poorly defined systems, developing technologies and evolving workflows seem to be a logical approach to provide added safeguards against medication errors. Summary: This article will review both the pros and cons of today's technologies and their ability to simplify the medication use process, reduce medication errors, improve documentation, improve healthcare costs and increase provider efficiency as relates to the use of antineoplastic therapy throughout the medication use process. Several technologies, mainly computerized provider order entry (CPOE), barcode medication administration (BCMA), smart pumps, electronic medication administration record (eMAR), and telepharmacy, have been well described and proven to reduce medication errors, improve adherence to quality metrics, and/or improve healthcare costs in a broad scope of patients. The utilization of these technologies during antineoplastic therapy is weak at best and lacking for most. Specific to the antineoplastic medication use system, the only technology with data to adequately support a claim of reduced medication errors is CPOE. In addition to the benefits these technologies can provide, it is also important to recognize their potential to induce new types of errors and inefficiencies which can negatively impact patient care. Conclusion: The utilization of technology reduces but does not eliminate the potential for error. The evidence base to support technology in preventing medication errors is limited in general but even more deficient in the realm of antineoplastic therapy. Though CPOE has the best evidence to support its use in the antineoplastic population, benefit from many other technologies may have to be inferred based on data from other patient populations. As health systems begin to widely adopt and implement new technologies it is important to critically assess their effectiveness in improving patient safety.

    Original languageEnglish (US)
    Pages (from-to)445-460
    Number of pages16
    JournalJournal of Oncology Pharmacy Practice
    Volume20
    Issue number6
    DOIs
    StatePublished - Dec 20 2014

    Fingerprint

    Patient Safety
    Medication Errors
    Antineoplastic Agents
    Technology
    Medical Order Entry Systems
    Health Care Costs
    Patient Care
    Medication Systems
    Medical Errors
    Workflow
    Therapeutics
    Documentation
    Population
    Health

    Keywords

    • chemotherapy errors
    • patient safety
    • Technology

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Oncology
    • Medicine(all)

    Cite this

    Bubalo, J., Warden, B. A., Wiegel, J. J., Nishida, T., Handel, E., Svoboda, L. M., ... Edillo, P. N. (2014). Does applying technology throughout the medication use process improve patient safety with antineoplastics? Journal of Oncology Pharmacy Practice, 20(6), 445-460. https://doi.org/10.1177/1078155213514469

    Does applying technology throughout the medication use process improve patient safety with antineoplastics? / Bubalo, Joseph; Warden, Bruce A.; Wiegel, Joshua J.; Nishida, Tess; Handel, Evelyn; Svoboda, Leanne M.; Nguyen, Lam; Edillo, P. Neil.

    In: Journal of Oncology Pharmacy Practice, Vol. 20, No. 6, 20.12.2014, p. 445-460.

    Research output: Contribution to journalArticle

    Bubalo, J, Warden, BA, Wiegel, JJ, Nishida, T, Handel, E, Svoboda, LM, Nguyen, L & Edillo, PN 2014, 'Does applying technology throughout the medication use process improve patient safety with antineoplastics?', Journal of Oncology Pharmacy Practice, vol. 20, no. 6, pp. 445-460. https://doi.org/10.1177/1078155213514469
    Bubalo, Joseph ; Warden, Bruce A. ; Wiegel, Joshua J. ; Nishida, Tess ; Handel, Evelyn ; Svoboda, Leanne M. ; Nguyen, Lam ; Edillo, P. Neil. / Does applying technology throughout the medication use process improve patient safety with antineoplastics?. In: Journal of Oncology Pharmacy Practice. 2014 ; Vol. 20, No. 6. pp. 445-460.
    @article{e8a5e78be24a4671b562354c5c0d4a38,
    title = "Does applying technology throughout the medication use process improve patient safety with antineoplastics?",
    abstract = "Purpose: Medical errors, in particular medication errors, continue to be a troublesome factor in the delivery of safe and effective patient care. Antineoplastic agents represent a group of medications highly susceptible to medication errors due to their complex regimens and narrow therapeutic indices. As the majority of these medication errors are frequently associated with breakdowns in poorly defined systems, developing technologies and evolving workflows seem to be a logical approach to provide added safeguards against medication errors. Summary: This article will review both the pros and cons of today's technologies and their ability to simplify the medication use process, reduce medication errors, improve documentation, improve healthcare costs and increase provider efficiency as relates to the use of antineoplastic therapy throughout the medication use process. Several technologies, mainly computerized provider order entry (CPOE), barcode medication administration (BCMA), smart pumps, electronic medication administration record (eMAR), and telepharmacy, have been well described and proven to reduce medication errors, improve adherence to quality metrics, and/or improve healthcare costs in a broad scope of patients. The utilization of these technologies during antineoplastic therapy is weak at best and lacking for most. Specific to the antineoplastic medication use system, the only technology with data to adequately support a claim of reduced medication errors is CPOE. In addition to the benefits these technologies can provide, it is also important to recognize their potential to induce new types of errors and inefficiencies which can negatively impact patient care. Conclusion: The utilization of technology reduces but does not eliminate the potential for error. The evidence base to support technology in preventing medication errors is limited in general but even more deficient in the realm of antineoplastic therapy. Though CPOE has the best evidence to support its use in the antineoplastic population, benefit from many other technologies may have to be inferred based on data from other patient populations. As health systems begin to widely adopt and implement new technologies it is important to critically assess their effectiveness in improving patient safety.",
    keywords = "chemotherapy errors, patient safety, Technology",
    author = "Joseph Bubalo and Warden, {Bruce A.} and Wiegel, {Joshua J.} and Tess Nishida and Evelyn Handel and Svoboda, {Leanne M.} and Lam Nguyen and Edillo, {P. Neil}",
    year = "2014",
    month = "12",
    day = "20",
    doi = "10.1177/1078155213514469",
    language = "English (US)",
    volume = "20",
    pages = "445--460",
    journal = "Journal of Oncology Pharmacy Practice",
    issn = "1078-1552",
    publisher = "SAGE Publications Ltd",
    number = "6",

    }

    TY - JOUR

    T1 - Does applying technology throughout the medication use process improve patient safety with antineoplastics?

    AU - Bubalo, Joseph

    AU - Warden, Bruce A.

    AU - Wiegel, Joshua J.

    AU - Nishida, Tess

    AU - Handel, Evelyn

    AU - Svoboda, Leanne M.

    AU - Nguyen, Lam

    AU - Edillo, P. Neil

    PY - 2014/12/20

    Y1 - 2014/12/20

    N2 - Purpose: Medical errors, in particular medication errors, continue to be a troublesome factor in the delivery of safe and effective patient care. Antineoplastic agents represent a group of medications highly susceptible to medication errors due to their complex regimens and narrow therapeutic indices. As the majority of these medication errors are frequently associated with breakdowns in poorly defined systems, developing technologies and evolving workflows seem to be a logical approach to provide added safeguards against medication errors. Summary: This article will review both the pros and cons of today's technologies and their ability to simplify the medication use process, reduce medication errors, improve documentation, improve healthcare costs and increase provider efficiency as relates to the use of antineoplastic therapy throughout the medication use process. Several technologies, mainly computerized provider order entry (CPOE), barcode medication administration (BCMA), smart pumps, electronic medication administration record (eMAR), and telepharmacy, have been well described and proven to reduce medication errors, improve adherence to quality metrics, and/or improve healthcare costs in a broad scope of patients. The utilization of these technologies during antineoplastic therapy is weak at best and lacking for most. Specific to the antineoplastic medication use system, the only technology with data to adequately support a claim of reduced medication errors is CPOE. In addition to the benefits these technologies can provide, it is also important to recognize their potential to induce new types of errors and inefficiencies which can negatively impact patient care. Conclusion: The utilization of technology reduces but does not eliminate the potential for error. The evidence base to support technology in preventing medication errors is limited in general but even more deficient in the realm of antineoplastic therapy. Though CPOE has the best evidence to support its use in the antineoplastic population, benefit from many other technologies may have to be inferred based on data from other patient populations. As health systems begin to widely adopt and implement new technologies it is important to critically assess their effectiveness in improving patient safety.

    AB - Purpose: Medical errors, in particular medication errors, continue to be a troublesome factor in the delivery of safe and effective patient care. Antineoplastic agents represent a group of medications highly susceptible to medication errors due to their complex regimens and narrow therapeutic indices. As the majority of these medication errors are frequently associated with breakdowns in poorly defined systems, developing technologies and evolving workflows seem to be a logical approach to provide added safeguards against medication errors. Summary: This article will review both the pros and cons of today's technologies and their ability to simplify the medication use process, reduce medication errors, improve documentation, improve healthcare costs and increase provider efficiency as relates to the use of antineoplastic therapy throughout the medication use process. Several technologies, mainly computerized provider order entry (CPOE), barcode medication administration (BCMA), smart pumps, electronic medication administration record (eMAR), and telepharmacy, have been well described and proven to reduce medication errors, improve adherence to quality metrics, and/or improve healthcare costs in a broad scope of patients. The utilization of these technologies during antineoplastic therapy is weak at best and lacking for most. Specific to the antineoplastic medication use system, the only technology with data to adequately support a claim of reduced medication errors is CPOE. In addition to the benefits these technologies can provide, it is also important to recognize their potential to induce new types of errors and inefficiencies which can negatively impact patient care. Conclusion: The utilization of technology reduces but does not eliminate the potential for error. The evidence base to support technology in preventing medication errors is limited in general but even more deficient in the realm of antineoplastic therapy. Though CPOE has the best evidence to support its use in the antineoplastic population, benefit from many other technologies may have to be inferred based on data from other patient populations. As health systems begin to widely adopt and implement new technologies it is important to critically assess their effectiveness in improving patient safety.

    KW - chemotherapy errors

    KW - patient safety

    KW - Technology

    UR - http://www.scopus.com/inward/record.url?scp=84911010141&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84911010141&partnerID=8YFLogxK

    U2 - 10.1177/1078155213514469

    DO - 10.1177/1078155213514469

    M3 - Article

    VL - 20

    SP - 445

    EP - 460

    JO - Journal of Oncology Pharmacy Practice

    JF - Journal of Oncology Pharmacy Practice

    SN - 1078-1552

    IS - 6

    ER -